TG Therapeutics Positive CHMP of BRIUMVI
TG Therapeutics, Inc. (TGTX), informed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of BRIUMVI™ (ublituximab-xiiy) for adults with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
BRIUMVI . . .